Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: A study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas

American Journal of Surgical Pathology

Volumn 31, Issue 10, 2007, Pages 1557-1566

  Binh, Matthieu Bui Nguyen ^a   Guillou, Louis ^b   Hostein, Isabelle ^c   Chĝteau, Marie Christine ^d   Collin, Francoise ^e   Aurias, Alain ^f   Binh, Bui Nguyen ^c   Stoeckle, Eberhard ^c   Coindre, Jean Michel ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE VAL D AURELLE   (France)

^e Georges Francois Leclerc Cancer Center   (France)

^f INSTITUT CURIE   (France)

Author keywords

Dedifferentiated liposarcoma; Leiomyosarcoma; Malignant mesenchymoma; Prognosis; Retroperitoneum; Rhabdomyosarcoma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALDESMON; CYCLIN DEPENDENT KINASE 4; DESMIN; MYOGENIN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN MDM2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; DIFFERENTIATION; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; MESENCHYMOMA; MYOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SARCOMA;

EID: 34748849536     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31804b4109     Document Type: Article

References (41)

1. Adachi T, Oda Y, Sakamoto A, et al. Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. Oncol Rep. 2003;10:803-811.
2. Bode-Lesniewska B, Zhao J, Speel E, et al. Gains of 12q13-14 and overexpression of MDM2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch. 2001;438:57-65.
3. Brady MS, Perino G, Tallini G, et al. Malignant mesenchymoma. Cancer. 1996;77:467-473.
4. Bui Nguyen Binh M, Sastre X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes. A comparative analysis of 561 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-1347.
5. Chibon F, Mairal A, Freneaux P, et al. The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. Cancer Res. 2000;60:6339-6345.
6. Chibon F, Mariani O, Derre J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet. 2002;139:24-29.
7. Coindre JM, Mariani O, Chibon F, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-262.
8. Coindre JM, Hostein I, Maire G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-830.
9. Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000;190:531-536.
10. Derre J, Lagace R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest. 2001;81:211-215.
11. Evans HL, Khurana KK, Kemp BL, et al. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol. 1994;18:1150-1157.
12. Fletcher CDM, Unni K, Mertens M. Pathology and Genetics of Tumours of Soft Tissue and Bone (World Health Organization Classification of Tumours). Oxford: University Press; 2004.
13. Folpe AL, Weiss SW. Lipoleiomyosarcoma (well-differentiated liposarcoma with leiomyosarcomatous differentiation): a clinico-pathologic study of nine cases including one with dedifferentiation. Am J Surg Pathol. 2002;26:742-749.
14. Forus A, Larramendy ML, Meza-Zepeda LA, et al. Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet Cytogenet. 2001;125:100-111.
15. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14:595-603.
16. Gaffney EF, Dervan PA, Fletcher CD. Pleomorphic rhabdomyosarcoma in adulthood. Analysis of 11 cases with definition of diagnostic criteria. Am J Surg Pathol. 1993;17:601-609.
17. Gamberi G, Ragazzini P, Benassi MS, et al. Analysis of 12q13-15 genes in parosteal osteosarcoma. Clin Orthop. 2000;377:195-204.
18. Gisselsson D, Palsson E, Hoglund M, et al. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer. 2002;33:133-140.
19. Gomez-Roman JJ, Val-Bernal JF. Lipoleiomyosarcoma of the mediastinum. Pathology. 1997;29:428-430.
20. Gordon A, McManus A, Anderson J, et al. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genet Cytogenet. 2003;140:73-77.
21. Henricks WH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997;21:271-281.
22. Hostein I, Pelmus M, Aurias A, et al. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol. 2004;202:95-102.
23. Mairal A, Terrier P, Chibon F, et al. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet. 1999;111:134-138.
24. McCormick D, Mentzel T, Beham A, et al. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol. 1994;18:1213-1223.
25. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and Morphology. Genes Chromosomes Cancer. 1998;22:16-25.
26. Micci F, Teixeira MR, Bjerkehagen B, et al. Characterization of supernumerary rings and giant marker chromosomes in well-differentiated lipomatous tumors by a combination of G-banding, CGH, M-FISH, and chromosome- and locus-specific FISH. Cytogenet Genome Res. 2002;97:13-19.
27. Miyajima K, Oda Y, Oshiro Y, et al. Clinicopathological prognostic factors in soft tissue leiomyosarcoma: a multivariate analysis. Histopathology. 2002;40:353-359.
28. Newman PL, Fletcher CD. Malignant mesenchymoma. Clinicopathologic analysis of a series with evidence of low-grade behaviour. Am J Surg Pathol. 1991;15:607-614.
29. Otano-Joos M, Mechtersheimer G, Ohl S, et al. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenet Cell Genet. 2000;90:86-92.
30. Park HR, Jung WW, Bertoni F, et al. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. Pathol Res Pract. 2004;200:439-445.
31. Pedeutour F, Suijkerbuijk RF, Van Gaal J, et al. Chromosome 12 origin in rings and giant markers in well-differentiated liposarcoma. Cancer Genet Cytogenet. 1993;66:133-134.
32. Pedeutour F, Suijkerbuijk RF, Forus A, et al. Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer. 1994;10:85-94.
33. Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer. 1999;24:30-41.
34. Pilotti S, Della Torre G, Mezzelani A, et al. The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer. 2000;82:1271-1275.
35. Pilotti S, Mezzelani A, Vergani B, et al. Morphologic-cytogenetic analysis of dedifferentiated liposarcomas with an extensive misleading leiomyosarcomatous component. Appl Immunohistochem Mol Morphol. 2000;8:216-221.
36. Salzano RP Jr, Tomkiewicz Z, Africano WA. Dedifferentiated liposarcoma with features of rhabdomyosarcoma. Conn Med. 1991;55:200-202.
37. Shanks JH, Banerjee SS, Eyden BP. Focal rhabdomyosarcomatous differentiation in primary liposarcoma. J Clin Pathol. 1996;49:770-772.
38. Shimada S, Ishizawa T, Ishizawa K, et al. Dedifferentiated liposarcoma with rhabdomyoblastic differentiation. Virchows Arch. 2005;447:835-841.
39. Simons A, Schepens M, Jeuken J, et al. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. Cancer Genet Cytogenet. 2000;118:89-98.
40. Suster S, Wong TY, Moran CA. Sarcomas with combined features of liposarcoma and leiomyosarcoma. Study of two cases of an unusual soft-tissue tumor showing dual lineage differentiation. Am J Surg Pathol. 1993;17:905-911.
41. Tallini G, Erlandson RA, Brennan MF, et al. Divergent myosarcomatous differentiation in retroperitoneal liposarcoma. Am J Surg Pathol. 1993;17:546-556.